EHA 2021 | Phase II study of naratuximab emtansine plus rituximab in DLBCL and other B-NHLs
Moshe Y. Levy, MD, Baylor Charles A. Sammons Cancer Center, Dallas, TX, discusses the results of a Phase I trial of naratuximab emtansine, an antibody-drug conjugate targeting CD37, in combination with rituximab for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and other types of B-cell non-Hodgkin lymphoma (B-NHL). Out of 100 patients enrolled in the study, 80 had DLBCL and 20 had other B-NHLs. Dr Levy discusses the poor prognosis for patients with R/R DLBCL who are not eligible for transplantation, and gives an overview of the rationale for the trial. Dr Levy reports that the drug combination demonstrated promising efficacy and was well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
